PriceTargets.com logo

Phio Pharmaceuticals - PHIO Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $36.00
  • Forecasted Upside: 1,622.49%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$2.09 As of 12/26/2024 06:41 PM ET
▼ -0.11 (-5.00%)

This chart shows the closing price for PHIO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Phio Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PHIO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PHIO

Analyst Price Target is $36.00
▲ +1,622.49% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Phio Pharmaceuticals in the last 3 months. The average price target is $36.00, with a high forecast of $36.00 and a low forecast of $36.00. The average price target represents a 1,622.49% upside from the last price of $2.09.

This chart shows the closing price for PHIO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 investment analysts is to buy stock in Phio Pharmaceuticals.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/5/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/3/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/1/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/31/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/29/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/27/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/26/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/26/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
5/14/2024HC WainwrightReiterated RatingBuy ➝ Buy$36.00
2/6/2024HC WainwrightLower TargetBuy ➝ Buy$54.00 ➝ $36.00
8/16/2023HC WainwrightReiterated RatingBuy ➝ Buy$54.00
1/12/2022HC WainwrightReiterated RatingBuy$54.00
11/15/2021HC WainwrightReiterated RatingBuy$54.00
6/14/2021HC WainwrightBoost TargetBuy$36.00 ➝ $54.00
8/14/2020HC WainwrightReiterated RatingBuy$36.00
8/5/2020HC WainwrightInitiated CoverageBuy$36.00
(Data available from 12/27/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
5/31/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/30/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/30/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/29/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/28/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
Mentions as of
10/28/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/27/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/27/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Phio Pharmaceuticals logo
Phio Pharmaceuticals Corp. engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors. It is also developing PH-894, an INTASYL compound in IND enabling studies to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, effecting the immune system and the tumor. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is based in Marlborough, Massachusetts.
Read More

Today's Range

Now: $2.09
Low: $1.89
High: $2.17

50 Day Range

MA: $2.71
Low: $1.74
High: $3.29

52 Week Range

Now: $2.09
Low: $1.53
High: $10.35

Volume

370,047 shs

Average Volume

116,627 shs

Market Capitalization

$2.20 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.49

Frequently Asked Questions

What sell-side analysts currently cover shares of Phio Pharmaceuticals?

The following Wall Street sell-side analysts have issued stock ratings on Phio Pharmaceuticals in the last twelve months: HC Wainwright.
View the latest analyst ratings for PHIO.

What is the current price target for Phio Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Phio Pharmaceuticals in the last year. Their average twelve-month price target is $36.00, suggesting a possible upside of 1,622.5%. HC Wainwright has the highest price target set, predicting PHIO will reach $36.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $36.00 for Phio Pharmaceuticals in the next year.
View the latest price targets for PHIO.

What is the current consensus analyst rating for Phio Pharmaceuticals?

Phio Pharmaceuticals currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PHIO will outperform the market and that investors should add to their positions of Phio Pharmaceuticals.
View the latest ratings for PHIO.

What other companies compete with Phio Pharmaceuticals?

Other companies that are similar to Phio Pharmaceuticals include BioCardia, Viracta Therapeutics, Indaptus Therapeutics, Aytu BioPharma and Cyclerion Therapeutics. Learn More about companies similar to Phio Pharmaceuticals.

How do I contact Phio Pharmaceuticals' investor relations team?

Phio Pharmaceuticals' physical mailing address is 257 SIMARANO DRIVE SUITE 101, MARLBOROUGH MA, 01752. The company's listed phone number is (508) 767-3861 and its investor relations email address is [email protected]. The official website for Phio Pharmaceuticals is phiopharma.com. Learn More about contacing Phio Pharmaceuticals investor relations.